BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Gennep S, Konté K, Meijer B, Heymans MW, D'Haens GR, Löwenberg M, de Boer NKH. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Aliment Pharmacol Ther 2019;50:484-506. [PMID: 31342537 DOI: 10.1111/apt.15403] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 van den Bosch BJ, Coenen MJ. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021;22:55-66. [PMID: 33305616 DOI: 10.2217/pgs-2020-0095] [Reference Citation Analysis]
2 Luber RP, Honap S, Cunningham G, Irving PM. Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases? Front Med (Lausanne) 2019;6:279. [PMID: 31850357 DOI: 10.3389/fmed.2019.00279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
3 Grover N, Bhatia P, Kumar A, Singh M, Lad D, Mandavdhare HS, Samanta J, Prasad KK, Dutta U, Sharma V. TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India. BMC Gastroenterol 2021;21:327. [PMID: 34425754 DOI: 10.1186/s12876-021-01900-8] [Reference Citation Analysis]
4 Coenen MJH. NUDT15 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease. Transl Gastroenterol Hepatol 2019;4:81. [PMID: 32039286 DOI: 10.21037/tgh.2019.11.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Puangpetch A, Tiyasirichokchai R, Pakakasama S, Wiwattanakul S, Anurathapan U, Hongeng S, Sukasem C. NUDT15 genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia. Pharmacogenomics 2020;21:403-10. [PMID: 32308129 DOI: 10.2217/pgs-2019-0177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zalizko P, Stefanovics J, Sokolovska J, Paramonova N, Klavina E, Erts R, Rovite V, Klovins J, Pukitis A. Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population. Therap Adv Gastroenterol 2020;13:1756284820937426. [PMID: 32704308 DOI: 10.1177/1756284820937426] [Reference Citation Analysis]
7 Séverine W, Xavier K, Jean-Charles C. A rare case of Azathioprine-induced leukopenia in an European woman. Acta Clin Belg 2022;77:163-7. [PMID: 32842934 DOI: 10.1080/17843286.2020.1812829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bayoumy AB, Mulder CJJ, Loganayagam A, Sanderson JD, Anderson S, Boekema PJ, Derijks LJJ, Ansari AR. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine. Ther Drug Monit 2021;43:617-23. [PMID: 34521801 DOI: 10.1097/FTD.0000000000000869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhu X, Chao K, Li M, Xie W, Zheng H, Zhang JX, Hu PJ, Huang M, Gao X, Wang XD. Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients. World J Gastroenterol 2019; 25(38): 5850-5861 [PMID: 31636477 DOI: 10.3748/wjg.v25.i38.5850] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Botros L, Szulcek R, Jansen SMA, Kurakula K, Goumans MTH, van Kuilenburg ABP, Vonk Noordegraaf A, de Man FS, Aman J, Bogaard HJ. The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2020;202:296-9. [DOI: 10.1164/rccm.202003-0473le] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
12 Nguyen ALH, Sparrow MP. Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. Dig Dis Sci 2021;66:3250-62. [PMID: 33073334 DOI: 10.1007/s10620-020-06662-z] [Reference Citation Analysis]
13 Imai T, Kawahara M, Tatsumi G, Yamashita N, Nishishita-Asai A, Inatomi O, Masamune A, Kakuta Y, Andoh A. Thiopurine Use During Pregnancy Has Deleterious Effects on Offspring in Nudt15R138C Knock-In Mice. Cell Mol Gastroenterol Hepatol 2021;12:335-7. [PMID: 33766784 DOI: 10.1016/j.jcmgh.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zeze K, Hirano A, Torisu T, Esaki M, Moriyama T, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Matsuno Y, Kitazono T. Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study. Dig Dis Sci 2021;66:3124-31. [PMID: 32920717 DOI: 10.1007/s10620-020-06600-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Daniel LL, Dickson AL, Chung CP. Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine. Clin Rheumatol 2021;40:65-73. [PMID: 32617765 DOI: 10.1007/s10067-020-05258-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Marinaki AM, Arenas-hernandez M. Reducing risk in thiopurine therapy. Xenobiotica 2020;50:101-9. [DOI: 10.1080/00498254.2019.1688424] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
17 Chao K, Huang Y, Zhu X, Tang J, Wang X, Lin L, Guo H, Zhang C, Li M, Yang Q, Huang J, Ye L, Hu P, Huang M, Cao Q, Gao X. Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. Aliment Pharmacol Ther 2021;54:1124-33. [PMID: 34563096 DOI: 10.1111/apt.16600] [Reference Citation Analysis]